The Analyst Verdict: XOMA Royalty In The Eyes Of 4 Experts
Analysts' ratings for XOMA Royalty (NASDAQ:XOMA) over the last quarter vary from bullish to bearish, as provided by 4 analysts.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 0 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 0 | 0 | 0 | 0 |
| 3M Ago | 1 | 0 | 0 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $108.75, along with a high estimate of $123.00 and a low estimate of $104.00. Highlighting a 4.19% decrease, the current average has fallen from the previous average price target of $113.50.
Interpreting Analyst Ratings: A Closer Look
An in-depth analysis of recent analyst actions unveils how financial experts perceive XOMA Royalty. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Joseph Pantginis | HC Wainwright & Co. | Maintains | Buy | $104.00 | $104.00 |
| Joseph Pantginis | HC Wainwright & Co. | Maintains | Buy | $104.00 | $104.00 |
| Joseph Pantginis | HC Wainwright & Co. | Lowers | Buy | $104.00 | $123.00 |
| Joseph Pantginis | HC Wainwright & Co. | Maintains | Buy | $123.00 | $123.00 |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to XOMA Royalty. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of XOMA Royalty compared to the broader market.
- Price Targets: Delving into movements, analysts provide estimates for the future value of XOMA Royalty's stock. This analysis reveals shifts in analysts' expectations over time.
To gain a panoramic view of XOMA Royalty's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on XOMA Royalty analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
About XOMA Royalty
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.
A Deep Dive into XOMA Royalty's Financials
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: XOMA Royalty displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 27.77%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: XOMA Royalty's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -227.84%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): XOMA Royalty's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -6.4%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): XOMA Royalty's ROA excels beyond industry benchmarks, reaching -2.4%. This signifies efficient management of assets and strong financial health.
Debt Management: XOMA Royalty's debt-to-equity ratio is below the industry average at 1.46, reflecting a lower dependency on debt financing and a more conservative financial approach.
Analyst Ratings: Simplified
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.